MedTrace Logo

the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis

NCT01116778 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 236

Last updated 2015-09-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of probiotics eN-Lac® capsules (Lactobacillus paracasei GMNL-32) for the treatment of children with perennial allergic rhinitis(PAR).

Conditions

  • Perennial Allergic Rhinitis
  • Probiotics
  • Lactobacillus Paracasei GMNL-32 (eN-Lac®)

Interventions

BIOLOGICAL

eN-Lac®

One capsule with 2x10\^9 colony forming unit (cfu) LP GMNL-32, once daily, po

OTHER

Placebo

One placebo capsule, once daily, po

Sponsors & Collaborators

  • Biomedical Development Corporation

    collaborator INDUSTRY

  • GenMont Biotech Incorporation

    lead INDUSTRY

Principal Investigators

  • Ying-Chen Lu, PhD · GenMont Biothech Incorporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-01-31
Completion
2012-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01116778 on ClinicalTrials.gov